Intermittent androgen blockade should be regarded as standard therapy in prostate cancer.
Seruga
Bostjan
B
Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada.
Tannock
Ian F
IF
D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000592:standards*; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D009362:Neoplasm Metastasis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis
D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen